ADRO News
Archived Headlines
- Pancreatic cancer biotech Aduro upsizes shares and increases proposed IPO price 04/14/15
- Week ahead: Crafts, cancer cures and cash flow in a week with 7 IPOs including Party City 04/13/15
- Pancreatic cancer biotech Aduro sets terms for $75 million IPO 04/06/15
- Pancreatic cancer biotech Aduro files for a $86 million IPO 03/11/15
US IPO Week Ahead: IPO market stays quiet during election week
There are currently no IPOs firmly scheduled to list in the week ahead as the US presidential election comes into view. One small issuer is tentatively on the calendar for the coming week though, and others may join the roster late. Currently listed on the CSE,...read more
US IPO Weekly Recap: 7 IPOs see Etsy vault 70%, proving vintage is in vogue
Etsy exploded 88% out of the gate, giving it the best first-day return for a tech IPO in over a year. Cancer immunotherapy biotech Aduro Biotech flew up 147%, the year's third IPO to more than double on day one. This past week was the second largest of 2015...read more
Aduro Biotech soars 100% on IPO
Aduro Biotech (ADRO) is the latest biotech IPO to soar on its public market debut, as the immunotherapy developer gained over 100%. Aduro boasts impressive backers, a large market opportunity and promising results from its Phase 2a trial for pancreatic...read more
Pancreatic cancer biotech Aduro prices upsized IPO at $17, above its original range
Aduro Biotech, which is developing two immunotherapy platforms for pancreatic and other cancers, raised $119 million by offering 7 million shares at $17; the company had originally proposed to sell 5 million shares at a $14 to $16 range before upsizing the deal...read more